Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

Objectives: Chronic lymphocytic leukemia (CLL) is a common form of leukemia with a heterogeneous clinical course that remains incurable due to the development of therapy resistance. In lymph node proliferation centers, signals from the microenvironment such as CD40 ligation through interaction with...

Full description

Bibliographic Details
Main Authors: Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater, Eric Eldering
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
CLL
CD40 activation
aCD20 immunotherapy
venetoclax
Online Access:https://www.mdpi.com/2072-6694/13/12/3084

Internet

https://www.mdpi.com/2072-6694/13/12/3084

Similar Items